The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|January 17, 2023
Rheumatoid Arthritis Quiz: Tapering Glucocorticoids
Author(s)Ingrid Torjesen
When is the right time to taper glucocorticoids and what is the correct approach? Take this quiz to test your knowledge.
Advertisement
Is the following statement true or false?
The American College of Rheumatology recommends tapering glucocorticoids for patients with low disease activity.
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement